Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

NVIDIA Announces BioNeMo Agent Toolkit — Tools for Agents to Accelerate Scientific Discovery

globenewswire.com
NVDA NVIDIA announced its BioNeMo Agent Toolkit, which provides tools for AI agents in the life sciences to accelerate scientific discovery. This is seen as a significant advancement, leveraging NVIDIA's expertise in AI and accelerated computing, and is expected to drive further innovation and adoption in the field. LRCX Lam Research is mentioned as a company that could benefit from the advancements in AI and accelerated computing, particularly in areas like chip design and manufacturing, which are crucial for AI development. However, the article does not provide specific details on Lam Research's direct involvement or impact. AMAT Applied Materials is indirectly relevant as a key player in the semiconductor equipment manufacturing sector, which supports the development of AI technologies. The article's focus on AI advancements suggests a positive environment for companies like Applied Materials, but no direct mention of their products or services is made. SNOW Snowflake is mentioned as a platform that is using the BioNeMo Agent Toolkit to connect data systems with AI-powered science. This integration suggests a positive use case for Snowflake's data cloud in the AI and life sciences sectors, but the article does not provide specific performance metrics or future outlook. CDNS Cadence Design Systems is mentioned as a provider of computer-aided drug discovery software that is integrating the BioNeMo Agent Toolkit's capabilities. This integration is expected to enhance their scientific applications, allowing agents to orchestrate molecular generation and prediction, but the article does not detail the specific impact or benefits. MRVL Marvell Technology is indirectly relevant as a provider of high-speed networking solutions crucial for AI data centers. The article's emphasis on AI infrastructure and accelerated computing suggests a favorable market environment for companies like Marvell, but there is no direct mention of their products or involvement. MU Micron Technology is indirectly relevant as a major producer of memory, a critical component for AI hardware. The article's focus on AI advancements and accelerated computing implies a strong demand for memory, but there is no specific mention of Micron's role or impact. SMCI Super Micro Computer is indirectly relevant as a supplier of high-performance servers and storage solutions essential for AI infrastructure. The article's focus on NVIDIA's AI advancements suggests a strong market for companies providing the underlying hardware, but Super Micro is not directly mentioned. AMD Advanced Micro Devices is indirectly relevant as a competitor and collaborator in the AI and semiconductor space. While the article highlights NVIDIA's advancements, the broader ecosystem implies a competitive and innovative landscape where AMD plays a significant role, though no specific mention is made. INTC Intel is indirectly relevant as a major player in the semiconductor industry, including AI-focused processors. The article's focus on AI advancements by NVIDIA suggests a dynamic market where Intel is also a key participant, but there is no direct mention of Intel's products or strategies in relation to the BioNeMo toolkit. QCOM Qualcomm is indirectly relevant as a provider of chips for various computing platforms, including those that could be used in AI applications. The article's focus on AI advancements suggests a growing market for semiconductor companies, but Qualcomm is not directly mentioned. GOOG Alphabet Inc. (Google) is mentioned as a potential user of AI agents and platforms, with its general-purpose assistants being a category that could integrate with tools like BioNeMo. However, the article does not specify any direct collaboration or use case for Google's AI services. MSFT Microsoft is mentioned as a potential user of AI agents and platforms, with its general-purpose assistants being a category that could integrate with tools like BioNeMo. However, the article does not specify any direct collaboration or use case for Microsoft's AI services. AMZN Amazon is mentioned as a potential user of AI agents and platforms, with its general-purpose assistants being a category that could integrate with tools like BioNeMo. However, the article does not specify any direct collaboration or use case for Amazon's AI services. LLY Eli Lilly and Company is mentioned as a diagnostics and pharmaceutical company using the BioNeMo Agent Toolkit to scale repeatable agentic workflows across discovery, translational research, and clinical insight. This indicates a positive adoption of NVIDIA's technology. NTRS Charles River Laboratories is indirectly relevant as a contract research organization that could leverage AI in drug discovery and development. The article's focus on accelerating scientific discovery through AI suggests a positive environment for such companies, but there is no direct mention. REGN Regeneron Pharmaceuticals is indirectly relevant as a biopharmaceutical company that could benefit from AI-driven drug discovery. The article's emphasis on accelerating scientific discovery through AI suggests a positive trend for companies in this sector, but there is no direct mention. GILD Gilead Sciences is indirectly relevant as a biopharmaceutical company that could benefit from AI-driven drug discovery. The article's emphasis on accelerating scientific discovery through AI suggests a positive trend for companies in this sector, but there is no direct mention. BMY Bristol Myers Squibb is indirectly relevant as a biopharmaceutical company that could benefit from AI-driven drug discovery. The article's emphasis on accelerating scientific discovery through AI suggests a positive trend for companies in this sector, but there is no direct mention. PFE Pfizer is indirectly relevant as a biopharmaceutical company that could benefit from AI-driven drug discovery. The article's emphasis on accelerating scientific discovery through AI suggests a positive trend for companies in this sector, but there is no direct mention. MRNA Moderna is indirectly relevant as a biotechnology company that could benefit from AI-driven research. The article's focus on accelerating scientific discovery through AI suggests a positive trend for companies in this sector, but there is no direct mention. BIIB Biogen is indirectly relevant as a biotechnology company that could benefit from AI-driven research. The article's focus on accelerating scientific discovery through AI suggests a positive trend for companies in this sector, but there is no direct mention. VRTX Vertex Pharmaceuticals is indirectly relevant as a biotechnology company that could benefit from AI-driven research. The article's focus on accelerating scientific discovery through AI suggests a positive trend for companies in this sector, but there is no direct mention. CRSP CRISPR Therapeutics is indirectly relevant as a biotechnology company that could benefit from AI-driven research. The article's focus on accelerating scientific discovery through AI suggests a positive trend for companies in this sector, but there is no direct mention. EXAS Exact Sciences is indirectly relevant as a diagnostics company that could benefit from AI in its research and development. The article's focus on accelerating scientific discovery through AI suggests a positive trend for companies in this sector, but there is no direct mention. ROST Ross Stores is not mentioned in the article and has no apparent connection to the topics discussed regarding NVIDIA's BioNeMo Agent Toolkit or AI in life sciences. DSY Dassault Systèmes is mentioned as a provider of computer-aided drug discovery software that is integrating the BioNeMo Agent Toolkit's capabilities. This integration is expected to enhance their scientific applications, allowing agents to orchestrate molecular generation and prediction, but the article does not detail the specific impact or benefits. TMO Thermo Fisher Scientific is mentioned as a company in the lab instruments and automation sector that is connecting systems with computational discovery powered by BioNeMo skills. This indicates a positive integration with NVIDIA's technology.

NVIDIA Announces BioNeMo Agent Toolkit — Tools for Agents to Accelerate Scientific Discovery News Summary:

SAN DIEGO, June 23, 2026 (GLOBE NEWSWIRE) -- BIO -- NVIDIA today announced NVIDIA BioNeMo Agent Toolkit, which provides domain-specific tools and skills for the agentic life sciences era.

Including more than a decade’s worth of NVIDIA life sciences libraries, tools and open models, the toolkit enables AI agents, scientists and labs to work together by gathering evidence, reasoning across findings, running computational experiments and recommending the next best steps to accelerate discovery.

It gives any agent or AI platform — from general-purpose assistants to specialized scientific agents, software platforms and in-house biopharma systems — the tools needed to synthesize and summarize scientific knowledge, call models, evaluate results, reason and execute next actions.

The toolkit includes NVIDIA BioNeMo™ and is powered by NVIDIA NIM™ microservices, NVIDIA Parabricks ®, NVIDIA NeMo™ and NVIDIA Nemotron™ technologies, along with accelerated computing and skills — providing an open and trusted foundation for agentic life sciences.

More than 50 leading companies are already using it to advance scientific discovery, tapping into agent-callable skills for tasks including protein structure prediction, molecular docking, generative chemistry, genomic analysis, protein design and biomarker discovery.

“Frontier models are the brains. BioNeMo is the scientific toolbox. Together, they give AI agents the skills of a PhD research assistant and the speed of a supercomputer,” said Jensen Huang, founder and CEO of NVIDIA. “For the first time, researchers can build AI agents that understand scientific knowledge, use scientific tools and execute scientific workflows. This is a new way to do science — one that can dramatically accelerate discovery across biology, chemistry, genomics and medicine.”

Open model and research organizations — including the Arc Institute, Open Molecular Software Foundation and the University of Washington’s Institute for Protein Design (IPD) — are working with NVIDIA to use BioNeMo to advance frontier models and make them more accessible through agent-ready workflows. The IPD collaboration has accelerated runtimes for state-of-the-art biodesign models like RosettaFold3, resulting in 2x faster performance than the prior-generation model, and many additional applications to accelerate protein design efforts are ongoing, giving researchers tools at a scale and cost not before possible.

“Every tool we’ve built for protein design is only as powerful as the scientists who can efficiently access it,” said David Baker, professor of biochemistry at the University of Washington School of Medicine and director of the Institute for Protein Design. “The next leap in science won’t come from a single discovery; it will come from the speed of iterative designs and agents that can repeatedly reason through the complexity of biology at a speed humans never could.”

Agent-Ready Tools and Skills for Life Sciences

Life sciences is one of the world’s most important scientific frontiers, with global scientific R&D reaching $3.8 trillion and annual pharmaceutical budgets approaching $300 billion.

Agentic workflows can help the industry iterate faster while reducing costs and maximizing the probability of success. With the toolkit allowing developers to transform general-purpose agents into life sciences agents in minutes, researchers can run experiments faster, continuously learn from results and close the loop between hypothesis and discovery, with some companies extending this iteration into physical labs.

A general-purpose agent can struggle to navigate scientific workflows efficiently, needing to infer the correct tools, inputs, outputs and biological meaning along the way. With BioNeMo Agent Toolkit, agents can call the right tools, interpret results more accurately and gain scientific insights faster and more reliably.

NVIDIA is optimizing the entire BioNeMo platform by turning libraries, models and frameworks into agent-callable tools.

This includes harnessing NVIDIA Agent Toolkit technologies such as NVIDIA Nemotron open models for the reasoning foundation, the NVIDIA NeMo RL library for reinforcement learning and NVIDIA NemoClaw™ blueprints for secure, private agents that can reason across tasks, call tools and interact with data continuously.

NVIDIA NIM microservices help agents call models and perform tasks. The NVIDIA OpenShell™ runtime provides a controlled executable environment.

The toolkit’s components enable agents to complete workflows such as:

Life Sciences Ecosystem Builds With NVIDIA BioNeMo

Companies across the technology and life sciences ecosystem are using the toolkit to advance agentic workflows.

Frontier labs and scientific agent builders including Anthropic, Edison Scientific, Lila Sciences, OpenAI and Owkin are integrating with BioNeMo to help agents move from answering questions to completing scientific work. NVIDIA accelerated models and analysis libraries help shorten the time from hypothesis to insight.

Scientific data and workflow platforms from Benchling, Certara, Databricks, Snowflake and Seqera are using BioNeMo Agent Toolkit to connect data systems with AI-powered science. BioNeMo skills can help agents query biological and chemical datasets, prepare model-ready inputs, launch reproducible workflows, analyze outputs and return insights directly within the platforms scientists and data teams already use daily.

Diagnostics and pharmaceutical companies including Lilly and Natera are using BioNeMo Agent Toolkit to scale repeatable agentic workflows across discovery, translational research and clinical insight.

AI-native biology companies including Boltz, Basecamp Research, Chai Discovery, Dyno, PerturbAI and Proxima have collaborated with NVIDIA to develop tools to accelerate model-powered therapeutic design workflows.

Computer-aided drug discovery software providers including Dassault Systèmes, Cadence (OpenEye) and Schrödinger are integrating the toolkit’s capabilities into scientific applications used across discovery teams. Then, agents can help orchestrate molecular generation, docking and prediction, turning computer-aided design platforms into systems where researchers can ask questions, launch analyses and identify next-best actions faster.

Lab instruments and automation companies including Automata, HighRes, Tecan, Thermo Fisher and autonomous data generation platform Medra are connecting systems with computational discovery powered by BioNeMo skills.

AI clouds and AI infrastructure companies including Baseten, Modal and Nebius are using the toolkit to help developers build life sciences workflows as reliable hosted services. By supporting BioNeMo skills and tools through scalable application programming interfaces, managed compute and production inference environments, these companies can help move agentic biology workflows from prototypes into accessible services for researchers and enterprises.

Availability

BioNeMo Agent Toolkit and skills are available now through the NVIDIA developer resources page and GitHub.

About NVIDIA

NVIDIA is the world leader in AI and accelerated computing.

For further information, contact:

Janette Ciborowski

Corporate Communications

NVIDIA Corporation

press@nvidia.com

Certain statements in this press release including, but not limited to, statements as to: for the first time, researchers being able to build AI agents that understand scientific knowledge, use scientific tools and execute scientific workflows; expectations with respect to growth, performance, availability, and benefits of NVIDIA’s products, services and technologies, and related trends and drivers; expectations with respect to NVIDIA’s third party arrangements, including with its collaborators and partners; expectations with respect to technology developments, and related trends and drivers; projected market growth and trends; expectations with respect to AI and related industries; and other statements that are not historical facts are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections based on management’s beliefs and assumptions and on information currently available to management and are subject to risks and uncertainties that could cause results to be materially different than expectations. Important factors that could cause actual results to differ materially include: global economic and political conditions; NVIDIA’s reliance on third parties to manufacture, assemble, package and test NVIDIA’s products; the impact of technological development and competition; development of new products and technologies or enhancements to NVIDIA’s existing products and technologies; market acceptance of NVIDIA’s products or NVIDIA’s partners’ products; design, manufacturing or software defects; changes in consumer preferences or demands; changes in industry standards and interfaces; unexpected loss of performance of NVIDIA’s products or technologies when integrated into systems; NVIDIA’s ability to realize the potential benefits of business investments or acquisitions; and changes in applicable laws and regulations, as well as other factors detailed from time to time in the most recent reports NVIDIA files with the Securities and Exchange Commission, or SEC, including, but not limited to, its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Copies of reports filed with the SEC are posted on the company’s website and are available from NVIDIA without charge. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, NVIDIA disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.

© 2026 NVIDIA Corporation. All rights reserved. NVIDIA, the NVIDIA logo, BioNeMo, NemoClaw, Nemotron, NVIDIA NeMo, NVIDIA NIM, NVIDIA OpenShell and Parabricks are trademarks and/or registered trademarks of NVIDIA Corporation in the U.S. and other countries. Other company and product names may be trademarks of the respective companies with which they are associated. Features, pricing, availability and specifications are subject to change without notice.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5ca024bb-1493-4542-96e6-7e98ec3c271c